Valuing Infectious Disease Deals: EBI's new Deal Valuation Tool
Executive SummaryThe growing problem of antibiotic resistance has forced big drug companies to take renewed interest in novel anti-infectives. Although the number of deals signed thus far in 2011 in this therapeutic area is lower than in prior years, licensing commitments have remained strong. Different deal structure scenarios based on the recent platform alliance between Sanofi and Rib-X are taken through EBI's new Strategic Transactions Deal Valuation Tool.
You may also be interested in...
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.